Search

Displaying results 9111 - 9120 of 9682 in total
  1. Drug

    Narnatumab

    go.drugbank.com/drugs/DB14964
    Investigational

    Narnatumab is under investigation in clinical trial NCT01119456 (A Study of IMC-RON8 in Advanced Solid Tumors).

  2. Drug

    Methamidophos

    go.drugbank.com/drugs/DB14972
    Experimental

    Methamidophos is under investigation in clinical trial NCT03223753 (Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia in First Remission).

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Abrocitinib

    go.drugbank.com/drugs/DB14973
    ApprovedInvestigational

    [L39774] The Janus kinase (JAK)–signal transducer and activator of transcription (STAT) signalling pathway plays a central role in the pathogenesis of a variety of autoimmune and inflammatory diseases, … including atopic dermatitis, a chronic inflammatory skin disease with complex pathogenesis.

  4. Drug

    Pimodivir

    go.drugbank.com/drugs/DB14974
    Investigational

    Pimodivir is under investigation in clinical trial NCT02658825 (A Study to Evaluate the Effect of JNJ-63623872 on Cardiac Repolarization Interval in Healthy Participants).

  5. Drug

    Voxelotor

    go.drugbank.com/drugs/DB14975
    Approved

    Voxelotor is a novel hemoglobin S polymerization inhibitor for the treatment of sickle cell disease. … This is a genetically inherited condition most prevalent in the Middle East, Africa, and certain parts of India.

  6. Drug

    Relacorilant

    go.drugbank.com/drugs/DB14976
    ApprovedInvestigational

    Relacorilant is a first-in-class, selective glucocorticoid receptor antagonist. … Originally investigated to manage the metabolic and endocrinologic complications of hypercortisolism, such as Cushing’s syndrome, its clinical utility has pivoted toward oncology as a potent sensitizing

  7. Drug

    Cimlanod

    go.drugbank.com/drugs/DB14983
    Investigational

    Cimlanod is under investigation in clinical trial NCT02819271 (A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers)

  8. Drug

    Casimersen

    go.drugbank.com/drugs/DB14984
    ApprovedInvestigational

    a six-membered morpholino ring, and the phosphodiester links between nucleotides are replaced with a phosphorodiamidate linkage. … A related, albeit a less severe, form of muscular dystrophy known as Becker muscular dystrophy (BMD) is characterized by shortened and partially functional dystrophin protein production.

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Difamilast

    go.drugbank.com/drugs/DB14987
    ApprovedInvestigational

    Atopic dermatitis is a chronic and fluctuating pruritic inflammatory skin condition characterized by pruritic eczema and is also marked by exacerbations and remissions. … [A275420] Difamilast is a selective PDE4 inhibitor and the inhibition of phosphodiesterase-4 (PDE4) reduces proinflammatory mediators and cytokines in atopic dermatitis.

  10. Drug

    Fitusiran

    go.drugbank.com/drugs/DB15002
    ApprovedInvestigational

    Fitusiran is an antithrombin-directed double-stranded small interfering ribonucleic acid (siRNA) that is covalently linked to a ligand containing a triantennary N-acetylgalactosamine (GalNAc) moiety. … [L52860] Fitusiran was first approved by the FDA on March 28, 2025, as routine prophylaxis therapy to prevent or reduce the frequency of bleeding episodes associated with hemophilia A or B.